We analyzed the G-actin-regulated transcriptome by gene expression analysis using previously characterized actin-binding drugs. We found many known MAL/MRTF-dependent target genes of serum response factor (SRF), as well as additional directly regulated genes. Surprisingly, several putative antiproliferative target genes were identified, including mig6/errfi-1, a negative regulator of the EGFR family. Mig6 induction occurred through actin-MAL-SRF signaling, and MAL was inducibly recruited to and activated a mig6 promoter element. Upregulation of Mig6 by lipid agonists such as LPA and S1P or actin drugs involved MAL and correlated with decreased activation of EGFR, MAPK/Erk, and c-fos. Mig6 depletion restored EGFR signaling and provided a proliferative advantage. Overexpression of MAL exhibited strong antiproliferative effects requiring the domains for SRF binding and transactivation, which supports antagonistic functions of MAL on growth-promoting signals. Our results show the existence of negatively acting transcriptional networks between pro-and antiproliferative signaling pathways toward SRF.
INTRODUCTION
Gene expression through the transcription factor serum response factor (SRF) is regulated by at least two signaling cascades controlling SRF-specific coactivators (Posern and Treisman, 2006) . Ternary complex factors (TCFs) such as Elk-1, SAP-1, and Net/SAP-2 are activated by mitogen-activated protein kinase (MAPK) phosphorylation. In a complex with SRF, these proteins make sequence-specific DNA contacts on some immediate early genes, e.g., the growth-promoting genes c-fos and egr-1 (Buchwalter et al., 2004) . G protein-coupled receptors (GPCRs) and receptor tyrosine kinases such as the EGFR transmit extracellular signals via Ras to the intracellular mitogenic cascade, ultimately resulting in TCF-dependent gene expression (Treisman, 1995) . Negative regulators such as Mig6/Errfi-1 (also known as RALT or gene 33), which inhibits the kinase of the EGFR family, are important modifiers of the mitogenic cascade (Fiorentino et al., 2000; Hackel et al., 2001; Xu et al., 2006; Zhang et al., 2007a) . Mig6 provides an autoinhibitory feedback loop and is required to prevent EGFR-dependent carcinogenesis (Ferby et al., 2006; Hackel et al., 2001; Zhang et al., 2007b) .
Recent work has established a novel signaling pathway regulating another subset of SRF target genes via coactivators of the myocardin-related transcription factor (MRTF) family, MAL/ MRTF-A/MKL1/BSAC and MRTF-B/MKL2 (Pipes et al., 2006; Posern and Treisman, 2006) . Their activation requires the Rho family GTPases RhoA or Rac and changes in actin dynamics (Busche et al., 2008; Du et al., 2004; Kuwahara et al., 2005; Posern et al., 2002; Sotiropoulos et al., 1999) . These changes are sensed by MAL, which harbors G-actin-binding RPEL motifs at the N terminus: Upon stimulation with Rho activators such as serum, lysophosphatidic acid (LPA), or sphingosine 1-phosphate (S1P), MAL is released from an inhibitory complex with monomeric, globular (G-) actin and strongly activates SRF-controlled transcription (Lockman et al., 2004; Miralles et al., 2003; Posern et al., 2004; Vartiainen et al., 2007) . Among the few known actin/MAL-dependent target genes are vcl, srf, cyr61, and several cytoskeletal genes whose activation is largely independent of MAPK signaling (Gineitis and Treisman, 2001; Miralles et al., 2003; Philippar et al., 2004) . These genes and their promoters respond differentially to actin-binding drugs: Treatment with cytochalasin D activates MAL-dependent transcription by releasing MAL from G-actin, while latrunculin B blocks the dissociation of the G-actin:MAL complex (Gineitis and Treisman, 2001; Miralles et al., 2003; Posern et al., 2002; Sotiropoulos et al., 1999; Vartiainen et al., 2007) . The subset of TCF-independent SRF target genes is also thought to play important roles in the phenotype of SRF-depleted mice, which show severe perturbations in cell adhesion, motility, and differentiation in various tissues, resulting in embryonic lethality (Arsenian et al., 1998; Balza and Misra, 2006; Knö ll et al., 2006; Koegel et al., 2009; Schratt et al., 2002) . However, depletion of MAL or MRTF-B leads to relatively mild and tissue-restricted phenotypes in myoepithelial and vascular smooth muscle cells, respectively (Li et al., 2005 (Li et al., , 2006 Oh et al., 2005; Sun et al., 2006b) . Transcription profiling of MAL-depleted mammary glands and cell lines revealed only partially overlapping gene expression patterns (Medjkane et al., 2009; Selvaraj and Prywes, 2004; Sun et al., 2006b) .
Here, we searched for genes that are directly regulated by G-actin, using the well-characterized actin drugs. We expected to find MAL-dependent SRF targets and potentially other G-actin-regulated genes. We found several known MAL/SRF targets and also unknown genes, many of which are involved in negative control of proliferation. Among those, we further characterized mig6 and showed that it is regulated via the G-actin-MAL-SRF signaling axis through a MAL-and SRF-binding promoter element. Induction of mig6 by actin drugs or lipid agonists attenuated the response to EGF signaling, demonstrating a negative crosstalk between the MAL and MAPK signaling modules. MAL exhibited strong antiproliferative effects through transcription, and we propose the existence of negatively acting transcriptional circuits to regulate signaling toward SRF.
RESULTS

Gene Expression Analysis for G-Actin-Regulated Targets
We and others have previously shown that G-actin regulates a transcriptional coactivator called MAL/MRTF-A/MKL1/BSAC (referred to as MAL) (Busche et al., 2008; Du et al., 2004; Kuwahara et al., 2005; Miralles et al., 2003) . This coactivator is involved in transcription via SRF and regulates a subset of known SRF target genes (Gineitis and Treisman, 2001; Lockman et al., 2004) . However, the plethora of G-actin-regulated genes remained unclear. Thus, we aimed at identifying G-actin target genes on a genome-wide basis. For this, we utilized actin-binding drugs that we recently characterized as differential activators or repressors of the actin-MAL pathway: Treatment with cytochalasin D activates MAL-dependent transcription by releasing MAL from G-actin, while latrunculin B blocks the dissociation of the G-actin:MAL complex. We reasoned that both drugs depolymerize F-actin, however: Genes depending on an intact cytoskeleton rather than on the G-actin switch should therefore not score as differentially expressed.
Thus, three conditions were used for the microarray analysis: control NIH 3T3 cells, cells treated with cytochalasin D, and cells treated with latrunculin B and cytochalasin D ( Figure 1A ). Optimal concentrations and times were established by reporter assays and validated by quantitative RT-PCR of known MAL-regulated SRF targets ( Figure S1 ). In addition, translation was blocked in all samples by cycloheximide to enrich primarily regulated targets and further reduce indirect effects from transcriptional circuits. Statistical analysis of three independent experiments per condition resulted in only 225 differentially regulated probe sets with a maximum false discovery rate (FDR) of 3.75; when this restriction was extended to a maximum FDR of 5.43, the number of differentially regulated probe sets increased marginally to 255 ( Table S1 ). Given that 45,000 probe sets were analyzed, this result suggested that a rather specific group of genes was differentially regulated by the combination of the three drugs.
The subsequent analysis of differentially regulated probe sets revealed that only 39 showed a downregulation by cytochalasin D; however, all of them were repressed by latrunculin B as well and thus failed our criteria for G-actin-regulated genes. Apparently, no inversely regulated group of genes exists that can respond to the same G-actin switch that activates MAL. The remaining 216 probe sets were upregulated by cytochalasin D and revealed a considerable reduction in the presence of latrunculin B (Table S1 ). Such differential regulation is not explainable by stress induction, since both drugs equally affect, e.g., the stress kinases p38 and JNK ( Figure S2 ).
Further analysis showed a striking accumulation of known MAL-dependent SRF targets among the genes strongly upregulated by cytochalasin D, serving as a positive control for the suitability of our approach ( Figure 1B) . Negative controls such as typical ''housekeeping'' genes did not show any significant regulation. More importantly, SRF targets such as c-fos and egr-1, which are mainly regulated by TCFs, failed to show statistically significant patterns of regulation by the actin drugs used ( Figure 1B ).
Beside many cytoskeletal target genes, we found, surprisingly, a large number of genes with presumed antiproliferative or proapoptotic function. These included the proapoptotic factors Pmaip/NOXA and Bok. We also identified Errfi-1, Dusp5, and Zfp36, which are negative regulators of the mitogenic cascade, at the level of the receptor kinases, the MAP kinase module, and the stability of target mRNAs, respectively ( Figure 1B ). For Errfi-1 (also known as RALT, gene 33, and mitogen-inducible gene 6; referred to as mig6), two independent probe sets were found. Their induction rates by cytochalasin D were 7.3-and 5-fold, and simultaneous treatment with latrunculin B reduced this value to 37% and 46%, respectively; calculated q values (i.e., the lowest FDR at which this particular probe set would be detected as differentially expressed) were zero ( Figure 1B ). To this end, we choose this gene for further analysis of its connection to G-actin-MAL signaling.
Validation of Mig6 as a G-Actin Target Gene
We first sought to validate mig6 induction in the absence of cycloheximide. Using quantitative real-time RT-PCR, we observed a 6-fold induction of mig6 mRNA by cytochalasin D within 90 min, which was reduced to less than 2-fold by pretreatment with latrunculin B (Figure 2A ). This pattern was comparable to ctgf, a previously characterized MAL/SRF target gene (Muehlich et al., 2007; Philippar et al., 2004 ). Next, we tested the accumulation of the Mig6 protein following treatment with various actin-binding drugs in several cell lines, including mouse embryo fibroblasts (MEFs) and hepatocellular carcinoma cells. Mig6 was induced by the two depolymerizing agents, cytochalasin D and swinholide A, as well as by the F-actin-stabilizing drug jasplakinolide ( Figure 2B ). In contrast, latrunculin B alone did not elevate Mig6, but partially blocked induction by cytochalasin D. This pattern of regulation by actin-binding drugs is known to be typical for MAL-dependent transcription (Miralles et al., 2003) .
The dose-response curve revealed that around 2 mM of cytochalasin D is sufficient for full Mig6 protein induction ( Figure 2C ). Time course analysis showed an observably increased Mig6 protein level after 3 hr of stimulation with cytochalasin or jasplakinolide, which was maintained for at least 7 hr ( Figure 2D ). Since MAPK Erk signaling is also known to stimulate Mig6 expression, we analyzed EGFR and Erk phosphorylation during this time course. However, we failed to observe pronounced induction of EGFR or Erk phosphorylation, in contrast to control cells treated with EGF ( Figure 2D ), suggesting that MAPK signaling is not causative for Mig6 induction by actin-binding drugs.
Together, Mig6 regulation on both mRNA and protein level occurred through G-actin, and the regulatory pattern is highly reminiscent of MAL-dependent SRF targets.
Regulation of Mig6 Transcription via MAL
To directly test Mig6 regulation, we transiently expressed activated constructs of MAL, its close relative myocardin, and A) Schematic description of the three conditions used for screening in NIH 3T3 fibroblasts. Control cells were treated with cycloheximide only (CHX, 3 mg/ml, 2 hr). G-actin-regulated genes were induced by treatment with cytochalasin D (CytoD, 2 mM, 90 min) and inhibited by latrunculin B (LatB, 5 mM). (B) List of some differentially regulated genes and controls. Shown is the induction (red) or repression (green) as a heat map. Genes are sorted according to the average fold induction by cytochalasin D (n = 3), with known MAL/SRF targets in italics. Average repression by latrunculin B is in comparison to the CytoD induction. The q value represents a measure of statistical significance. As controls, three housekeeping genes as well as two known MAL-independent SRF targets are depicted (lower panels). See Supplemental Data for more information.
SRF. An increased level of Mig6 protein was observed in the total lysates of MEFs ( Figure 3A) , despite a limited transfection rate of approximately 20%. Similarly, MAL DN and SRF-VP16 upregulated Mig6 in NIH 3T3 cells ( Figure 3A ). Full-length MAL was not sufficient to observably induce Mig6 in this assay, however, which is consistent with its weaker transcriptional effects due to tight regulation by upstream signaling. Concomitantly, the mRNA level for mig6 as well as the MAL and SRF target genes ctgf and integrin alpha 5 was upregulated by SRF-VP16, MAL DN, and activated RhoA Q63L, a potent inducer of MAL-SRF-controlled gene expression ( Figure 3B ). This suggests that activation of RhoA, MAL, and SRF correlates with mig6 transcription, similar to previously characterized MALdependent target genes.
The promoter of mig6 is thought to be 5 0 of an untranslated exon. We constructed various promoter-reporter constructs, ranging from À1635 to +1, and analyzed the luciferase activity in the presence or absence of activated MAL DN and SRF-VP16. A promoter element covering at least the 330 bp in front of the putative transcription start site contained a MAL-responsive element, while a further truncation to À147 abolished reporter induction by MAL DN ( Figure 3C ). Deletion of a putative CArG-like element at position À260 in the murine promoter rendered this reporter unresponsive to MAL ( Figure 3C ). This proximal element of the mig6 promoter is therefore required for regulation through MAL.
A fragment of the mig6 promoter, including the response element at À260, permitted MAL-and SRF-induced reporter activity when fused in front of a basal TATA box, whereas a mutated sequence showed significantly diminished inducibility ( Figure 3D ). Despite the lack of considerable induction by MAL DN, some responsiveness to SRF-VP16 was maintained; however, this was not mediated through the only other potential SRF-binding site at position À125 ( Figure S3 ).
Finally, we directly analyzed MAL and SRF recruitment to the mig6 promoter using chromatin immunoprecipitation (ChIP). The mig6 promoter covering the position À260 as well as the known target promoters of the vcl and srf genes were amplified from MAL immunoprecipitates upon serum stimulation, demonstrating an inducible recruitment ( Figure 3E ). Moreover, mig6, vcl , and srf promoters were also bound by the SRF protein. We note that SRF recruitment to mig6 and, to a lesser extent, to vcl and srf, appears to be slightly elevated following serum stimulation, but the significance of this remains to be tested. In contrast, a fragment within the first intron of mig6, or the gapdh gene, was not amplified from either MAL or SRF chromatin immunoprecipitates ( Figure 3E ). Together, our results suggest that mig6 is directly regulated by MAL through binding and activating a promoter region at À260 of the murine mig6 gene. 
Upregulated Mig6 Interferes with EGFR-MAPK Signaling
Mig6 is a negative regulator of receptor tyrosine kinases, and Mig6 depletion in mice results in elevated phosphorylation and activity of EGFR and MAPK Erk (Ferby et al., 2006) . Structural and biochemical evidence suggested that Mig6 blocks the formation of asymmetric EGFR dimers, thereby inhibiting the tyrosine kinase activity and the phosphorylation of critical C-terminal residues, including Y1173 (Anastasi et al., 2007; Zhang et al., 2007a) . We therefore investigated whether the observed upregulation of Mig6 has implications on the EGFR signaling axis. EGFR phosphorylation was analyzed first in HepG2 cells, which harbor low basal mig6 and high EGFR expression (M.R., unpublished data). Cells were pretreated with the actin-binding drugs cytochalasin or swinholide, allowing the accumulation of Mig6 ( Figure 4A ). Subsequent short-term activation by EGF showed a pronounced reduction in the Y1173 phosphorylation of the EGFR ( Figure 4A ), suggesting that the Mig6 induction by actin drugs downregulates signaling through EGFR.
The EGFR is also activated by amphiregulin and results in the stimulation of the MAP kinase Erk. We tested whether our Mig6 induction affects the level of activated phospho-Erk. Stimulation with amphiregulin for 30 min increased Erk phosphorylation without strongly stimulating Mig6 protein levels ( Figure 4B ). In contrast, cells with cytochalasin-induced Mig6 levels showed a decreased Erk phosphorylation after amphiregulin stimulation, suggesting that Mig6 induction though actin signaling interferes with the mitogenic cascade.
To test whether Mig6 is critical for reduced EGFR signaling after actin drug treatment, we generated a stable Mig6 knockdown in HepG2 cells. Although the knockdown of Mig6 protein appeared to be efficient in untreated control cells, the Mig6 induction by swinholide or jasplakinolide was reduced only incompletely ( Figure 4C ). However, the reduction of ligand-activated phospho-EGFR by either actin drug was no longer observable in the Mig6 knockdown cell line ( Figure 4C ), suggesting that reduced amounts of Mig6 abolish EGFR desensitization through actin signaling.
The desensitization of the EGFR was also observable in MEFs treated with cytochalasin or jasplakinolide and correlated with Mig6 induction ( Figure 4D , left panels). To address whether this is a direct consequence of Mig6 upregulation, we tested MEFs derived from Mig6 knockout mice. Cells depleted for Mig6 failed to show reduced EGFR phosphorylation following cytochalasin and jasplakinolide pretreatment ( Figure 4D ). Together, our results suggest that EGFR activity is negatively regulated by actincontrolled Mig6 induction.
Mig6 Induction by Physiological GPCR Ligands via MAL Next we sought to identify physiological stimuli that regulate Mig6 via MAL. Lipid agonists such as LPA and S1P are serum components and trigger MAL-SRF signaling via GPCRs (Gineitis and Treisman, 2001; Lockman et al., 2004) . We analyzed the time course of mig6 mRNA induction by these stimuli. Both LPA and S1P rapidly induced mig6 mRNA in NIH 3T3 cells within 30-20 min, comparable to the effect of cytochalasin D ( Figure 5A ). This induction was transient, and the mig6 mRNA level declined to background levels 3-4 hr after induction. A similar albeit higher induction was evident for stimulation by serum. Accordingly, an increase in Mig6 protein levels was also observable following immunofluorescence staining of serum-stimulated MEF and NIH 3T3 cells, in contrast to mig6-depleted control MEFs ( Figure S4 ).
To analyze whether this Mig6 induction occurs via activation of the MAL signaling axis, we first utilized the dominant-negative MAL constructs DNDC and DNDB. MAL DNDB lacks the binding domains for actin and SRF and retains endogenous MAL via the leucine zipper in an inactive, cytoplasmic state (Knö ll et al., 2006) . In electroporated NIH 3T3 cells, we observed a considerable reduction of LPA-or serum-stimulated mig6 mRNA by MAL DNDC and DNDB ( Figure 5B ), despite a relatively low transfection rate of $40% (data not shown).
Second, we reduced both MAL and MRTF-B expression to roughly 20% of the endogenous mRNA level using retroviral shRNA ( Figure 5C , right panels). This knockdown resulted in an $2-fold reduction of the mig6 mRNA induction by cytochalasin, LPA, or serum without affecting the basal mig6 level ( Figure 5C , left panels). Similarly affected was the known MAL target gene srf, whereas acta2 mRNA showed a stronger effect, but also background reduction. On protein level, Mig6 induction by LPA and serum was partially reverted by knockdown of MAL ( Figure 5D ), consistent with the mRNA data. Moreover, treatment with the cell-permeable Rho inhibitor Tat-C3 partially reduced Mig6 protein and mRNA induction by LPA and serum, but not by cytochalasin D (Figure S5 ). Together, these results show that actin-MAL signaling, likely in concert with other signals, contributes considerably to Mig6 upregulation by serum components and physiological GPCR ligands.
Mig6 Is Required for Desensitization of EGFR-MAPK
We investigated the consequences of the MAL-mediated Mig6 induction by GPCR ligands. Pretreatment with LPA resulted in the accumulation of Mig6 protein ( Figure 6A ). Subsequent stimulation with EGF resulted in reduced phosphorylation of EGFR, compared to cells that have not been pretreated with LPA. Importantly, this effect was strongly attenuated in cells depleted for mig6 ( Figure 6A ). The phosphorylation status of Y1173 is considered to reflect the signaling from EGFR to the MAPK Erk1/2, and we indeed observed a diminished Erk phosphorylation after LPA pretreatment in WT cells, but not in mig6 À/À MEFs ( Figure 6A ). These results strongly suggest that LPA desensitizes cells for EGFR-MAPK signaling and that this desensitization depends on Mig6 upregulation. In addition, determination of the cumulative cell number showed that the mig6 À/À MEFs exhibited an elevated growth curve compared to their WT counterparts ( Figure 6B ). This indicates that depletion of Mig6 provides a proliferative advantage. Signaling via the EGFR can also induce Mig6 expression and establish a negative feedback on MAPK signaling (Hackel et al., 2001) . We therefore investigated the relative contribution of the mitogenic cascade and actin signaling toward Mig6 induction. Indeed, extended mitogenic signaling by 7 hr of EGF treatment resulted in the expected Mig6 accumulation; however, this was much further increased by simultaneous treatment with cytochalasin ( Figure 6C ), which alone hardly induces Erk phosphorylation (compare Figures 2B and 4B ). This suggests that pronounced induction of Mig6 involves the G-actin-regulated transcription via MAL. Moreover, GPCR ligands transactivate the EGF receptors via a triple-membrane passing pathway requiring metalloprotease activity (Prenzel et al., 1999) . We thus asked whether the induction of Mig6 is mediated via EGFR transactivation rather than by actin-MAL signaling. When EGFR tyrosine kinase was inhibited using the tyrphostin AG1478, however, we did not observe a block in Mig6 protein induction by extended serum or LPA treatment ( Figure 6D) . Similarly, the metalloprotease inhibitor batimastat/BB94 did not inhibit Mig6 induction ( Figure 6D ), while transactivation of EGFR family members by serum or LPA was (E) MAL and SRF recruitment to the mig6 promoter. ChIP was performed using starved and stimulated (15% FCS, 30 min) cells and antibodies specific for SRF and MAL or a negative control antibody. Bound gapdh, vinc, srf, and mig6 promoters were amplified by conventional PCR and visualized on agarose gels (top panels) or quantified by real-time PCR from three independent chromatin preparations (bottom). As an additional negative control, primers spanning the first intron of mig6 were used. ). Subsequently, they were stimulated with EGF (25 ng/ml) for 30 min when indicated, and total lysates were subjected to immunoblotting with antibodies specific for tyrosine-phosphorylated EGFR, Mig6, or tubulin as a control. (B) Cells were pretreated with actin drugs as in (A) and subsequently stimulated with amphiregulin (Areg, 50 ng/ml). Erk activity was determined by immunoblotting with phosphospecific anti-Erk and panErk antibodies. effectively blocked by either inhibitor ( Figure S6 ). These findings support a critical role of actin-MAL signaling, whereas transactivation of the EGFR pathway appears to be less important for Mig6 induction upon extended treatment with lipid agonists.
Finally, we analyzed the mRNA level of c-fos, which is thought to be mainly controlled through MAPK-dependent phosphorylation of TCFs in NIH 3T3 fibroblasts (Gineitis and Treisman, 2001; Murai and Treisman, 2002; Sotiropoulos et al., 1999) . As expected, EGF stimulation strongly induced endogenous c-fos expression. This induction was significantly reduced following LPA or S1P pretreatment ( Figure 6E ). Moreover, this reduction was not affected by batimastat/BB94. These results suggest Antiproliferative Effects of MAL Depend on Transactivation and SRF Prompted by our finding that several of the newly identified G-actin-regulated genes exhibit putative or proven antiproliferative functions, we investigated the role of MAL on cell proliferation. Using retroviral infection, we monitored the growth curves of cells expressing various MAL constructs. In contrast to the GFP-infected control cells, MAL-overexpressing cells showed considerably reduced cumulative cell numbers over 7 days following infection ( Figure 7A ). This effect was augmented by deletion of the regulatory N-terminal domain of MAL that harbors the G-actin-binding RPEL motifs, even though the expression of this MAL DN protein was lower ( Figure 7B ). This demonstrated that MAL harbors antiproliferative activity when overexpressed.
To test whether the reduction of cell numbers is facilitated by binding of MAL to SRF and transcriptional activation, we also tested deletions in the B-box required for SRF-binding and in the C-terminal transactivation domain. Both deletions, however, reversed the antiproliferative effect of MAL DN, suggesting that transcriptional activation of SRF target genes is causal for the altered growth curves.
In addition to decreased proliferation, overexpression of MAL and activated MAL DN was incompatible with colony formation during selection of stably infected cells ( Figures 7C and 7D ). While MAL DNDB and DNDC permitted colony formation similar to GFP-infected controls, hardly any colonies were observed in both NIH 3T3 fibroblasts and NBT-II epithelial cells infected with MAL and MAL DN ( Figures 7C and 7D ). This suggests that the remaining cells monitored in the growth curves were likely not expressing active MAL proteins, despite infection rates usually higher than 90% ( Figure 7D , top right). Preliminary analysis of this deleterious effect of MAL overexpression indicated an involvement of apoptosis ( Figure S7 ). In support of this, we repeatedly failed to establish stable cell lines overexpressing MAL DN, even when utilizing inducible systems (data not shown).
Remarkably, phase contrast microscopy of transiently infected NIH cells revealed a change of cell morphology in addition to the reduction of cell numbers ( Figure 7D ). The effect was gradual, being moderate in MAL and more prominent in MAL DN-infected cells, which are more spread out and form planar as well as pointed protrusions. Cell densities were kept low in these experiments, however; a role of enhanced contact inhibition in the reduction of proliferation can thus be excluded ( Figure 7A ). The changed morphology was not indicative for induced senescence, since b-galactosidase staining proved negative (data not shown). We note that the morphological alterations could potentially be explained by upregulation of cytoskeletal components identified as G-actin-regulated MAL-SRF target genes, although it remains to be investigated whether they also contribute to the antiproliferative effects of MAL reported here.
DISCUSSION
We previously identified and characterized a signaling pathway by which monomeric actin directly impinges on gene expression in fibroblasts and epithelial cells (Busche et al., 2008; Miralles et al., 2003) . This interesting connection between a major building block of the cytoskeleton, the actin, and transcription through the DNA-binding SRF is mediated by the coactivator MAL. However, SRF-dependent transcription can also be regulated via the MAPK pathway, leading to phosphorylation of TCFs such as Elk-1, and some evidence exists that the two cohorts of target genes regulated by either coactivator are at least partially distinct (Gineitis and Treisman, 2001; Lockman et al., 2004; Miralles et al., 2003) . Several experimental approaches using SRF knockout cells (Balza and Misra, 2006; Etkin et al., 2006; Philippar et al., 2004) as well as ChIP-on-chip and computational algorithms (Cooper et al., 2007; Sun et al., 2006a ) have identified many SRF target genes, but they could not distinguish between the two cohorts.
Our gene expression analysis identified G-actin-regulated target genes in fibroblasts. Strikingly, they include many previously known MAL-dependent SRF targets, but exclude known TCF-dependent targets such as the prototypical growthpromoting oncogenes c-fos and egr-1, thereby nicely validating our approach. In addition, the layout of our screen allowed for the identification of other genes that are regulated by a comparable actin-based switch, but independently of MAL/SRF. Considering that conserved biochemical mechanisms are often utilized more than once by cellular processes, such targets would have been of particular interest. As yet, however, we did not find any G-actin-regulated but MAL/SRF-independent genes: First, we failed to identify a group of genes that are repressed by cytochalasin and induced by latrunculin. Second, the percentage of differentially expressed genes that were previously described as MAL or SRF targets is unexpectedly high. Third, all of the newly identified G-actin-regulated genes tested so far responded to either MAL or SRF-VP16 (data not shown). Thus, we speculate that G-actin-regulated genes that are independent of MAL/SRF may not exist, at least not in fibroblasts.
The chosen microarray approach turned out to be relatively selective, since we reduced indirect effects through newly synthesized proteins by a relatively short stimulation and by blocking translation with cycloheximide. The importance of this is emphasized by the identified target genes, which strongly suggest a multitude of transcriptional circuitries. In addition, cycloheximide is known to cause superinduction of immediate early genes, which may have further enhanced specific gene expression. Previous approaches to identify MAL-dependent target genes often could not distinguish between directly and indirectly regulated transcription, and they identified only a small proportion of the MAL-regulated transcriptome (Selvaraj and Prywes, 2004; Sun et al., 2006b ). Nevertheless, we note that many of the downregulated genes from MAL-depleted mammary glands and cancer cell lines are included in our list, e.g., calponin, tropomyosin, Myl9, and Myh9 (Medjkane et al., 2009; Sun et al., 2006b ). In contrast, there is little overall consistency with the list of genes whose serum induction is reduced by expression of the dominant-negative MAL DC (Selvaraj and Prywes, 2004) : This construct binds to SRF and may indirectly block TCF-mediated transcription, resulting in partial misclassification of MAL-dependent and MAL-independent gene expression. (A) WT or mig6 knockout MEFs were treated with LPA for 7 hr prior to EGF stimulation (40 ng/ml). Activation of EGFR and MAPK Erk was determined by immunoblotting with phosphospecific EGFR and Erk antibodies. Densitometric quantification of the relative EGFR phosphorylation upon EGF stimulation is shown by the bar chart. (B) Depletion of Mig6 provides a proliferative advantage for MEFs cultivated in serum-containing medium. Over a period of 5 days, the cumulative cell number was determined in triplicates (± SD). (C) Induction of endogenous Mig6 by long-term stimulation (7 hr) with EGF alone or in combination with cytochalasin D. Lysates were immunoblotted with antibodies against Mig6, with panErk as a control. (D) Mig6 upregulation by serum or lipid agonists is largely independent of EGFR transactivation. MEFs were pretreated with the EGFR kinase inhibitor AG1478 or the metalloprotease inhibitor BB94 for 30 min, followed by stimulation with FCS or S1P for 7 hr. (E) c-fos mRNA induction. NIH 3T3 fibroblasts were pretreated and stimulated with EGF as before. Endogenous c-fos expression was analyzed by quantitative RT-PCR. Shown is the average induction to unstimulated cells (un.) after normalization to hprt. Error bars, SEM (n = 3). *, significant repression (p < 0.01).
Our study identifies the negative regulator of the EGFR-MAPK signaling cascade, Mig6/Errfi-1, as a G-actin-regulated target gene. The data demonstrate that mig6 is indeed transcriptionally upregulated by actin-MAL signaling and, as a consequence, alleviates MAPK signaling. Thus, we describe a negative feedback circuit between the actin-MAL and the MAPK-TCF pathways, which both regulate SRF-dependent transcription ( Figure 7E ). The crosstalk via mig6 occurs at the level of the receptor tyrosine kinase activity. In addition, our gene expression analysis raises the possibility that this is not the only way actin-regulated transcription negatively feeds into the MAPK cascade: the dual specificity phosphatase DUSP5, a negative regulator of Erk (Mandl et al., 2005) , is also upregulated. Thus, we speculate that negatively acting transcriptional networks are tightly interwoven into the regulation of the two signaling pathways and contribute to signal termination following complex stimuli.
Mutual regulation of SRF targets has previously been shown at the promoter level, where recruitment of either cofactor to SRF precludes the binding of the other cofactor by occupying the same SRF surface (Murai and Treisman, 2002; Wang et al., 2004; Zaromytidou et al., 2006) . Consequently, SRF-dependent smooth muscle differentiation genes such as sm22, sm-a-actin, and telokin are effectively repressed by
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Elk-1 upon proliferative stimuli, because activated Elk-1 competes with the much stronger transactivator and MAL homolog myocardin for SRF binding (Wang et al., 2004; Zhou et al., 2005) . Moreover, the transcriptional activity of MAL in fibroblasts is negatively regulated by phosphorylation through Erk, which enhances nuclear export of G-actin:MAL complexes (Muehlich et al., 2008) . By showing that actin-MAL signaling conversely attenuates the EGFR-MAPK pathway, our work adds further evidence to the concept of multiple negative crosstalks between the two pathways, which appear to exist in both directions and on several levels.
The MAL protein elicits a strong antiproliferative effect when overexpressed in various cell lines, including MEFs, NIH 3T3, and NBT-II. This effect apparently depends on SRF-mediated transcription, as inferred from its abrogation in mutants defective for transactivation or SRF binding. At first, this seems surprising for a component of serum and lipid agonist signaling, and it remains to be determined whether activation of endogenous MAL elicits a similar effect. Recent evidence, however, suggests that antiproliferative effects also apply to other MRTF family members (Chen et al., 2002; Milyavsky et al., 2007) . Myocardin, which constitutively activates SRF target genes in cardiac and smooth muscle, was recently identified as a tumor suppressor in sarcomas, and its expression in various human tumors is reduced (Milyavsky et al., 2007) . Myocardin suppresses NFkBmediated cell cycle progression by binding and inhibiting p65 (Tang et al., 2008) . In addition, the oncogenic fusion protein OTT-MAL harbors strong antiproliferative potential in tissue culture (Descot et al., 2008) . The antiproliferative target genes identified in our array may provide new molecular explanations for the growth-suppressive function of the MRTF family. We propose, however, that the antiproliferative MAL effect is not monogenic, but may be the sum of various factors. Thus, knockdown of single target genes such as mig6 are unlikely to reverse the MAL-mediated proliferation block, and initial experiments support this hypothesis (data not shown).
In contrast to the antiproliferative effects of MAL, a variant isoform named BSAC was identified in a screen for suppressors of TNF-induced cell death (Sasazuki et al., 2002) . In the highly apoptosis-susceptible Traf2/Traf5 double knockout cells, TNFinduced death was rescued by BSAC, indicating that BSAC negatively regulates TNF signaling (Sasazuki et al., 2002) . Indeed, anti-apoptotic factors such as Bcl-2 have been identified as SRF target genes, and Bcl-2 restores survival of the Traf2/Traf5 double knockout cells as well as differentiating srf À/À embryonic stem cells (Sasazuki et al., 2002; Schratt et al., 2004) . Thus, Bcl-2 induction may bring about anti-apoptotic MAL/SRF effects under particular circumstances. However, Bcl-2 is only 1 example of more than 150 described SRF targets, and its promoter responds only weakly to RhoA in NIH 3T3 cells (Schratt et al., 2004) ; we did not detect Bcl-2 among the differentially expressed genes in our microarray.
A recent study showed a hyperproliferative skin disease and impaired keratinocyte differentiation resulting from SRF depletion (Koegel et al., 2009) . Interestingly, we note that this essentially phenocopies some aspects of Mig6 knockout mice (Ferby et al., 2006) . It remains to be determined whether these similarities between SRF and Mig6 depletion are causally connected.
EXPERIMENTAL PROCEDURES
Plasmids, Cells, and Reagents For a detailed plasmid description, see Supplemental Data. WT and mig6 À/À MEFs were isolated from E13.5 embryos, which were separated from their placenta and surrounding membranes. The brain and dark organs were cut away, and tissue dissociation was performed by trypsinization for 15 min. Genotyping was done as described (Ferby et al., 2006) . NIH 3T3, MEFs, and HS817T were cultivated in DMEM supplemented with 10% FBS (GIBCO). HepG2 were grown in MEM supplemented with nonessential amino acids (0.1 mM), sodium bicarbonate (75 mg/l), and 10% FBS. For knockdown of Mig6, HepG2 cells were retrovirally infected and selected for 10 days by 1.5 mg/ml puromycin.
Cytochalasin D, latrunculin B, jasplakinolide, and puromycin were purchased from Calbiochem (Beeston, UK). Cycloheximide, LPA, S1P, EGF, and amphiregulin were from Sigma (Taufkirchen, Germany). AG1478 was from Alexis Biochemicals (Lö rrach, Germany) and Batimastat (BB94) from British Biotech (Oxford).
Transfections, Electroporations, and Infections
Transfections of NIH 3T3 cells were carried out with lipofectamine (Invitrogen), as described previously (Posern et al., 2004) . Electroporation of 8 3 10 6 MEFs or 5 3 10 6 NIH 3T3 cells was carried out in 400 ml of Opti-MEM (GIBCO) with 20 mg of DNA, using a GenePulser Xcell with CE and PC modules and the exponential decay protocol (voltage, 250 V; pulse length, 60 ms) in a 4 mm cuvette (Bio-Rad). Cells were seeded in 6 cm dishes in DMEM supplemented with 10% FCS and serum-starved 8 hr later. For infection, 6 3 10 6 cells of the retroviral packaging line Phoenix E were transfected on a 10 cm dish with 20 mg of plasmid using calcium phosphate. Following virus production for 24 hr, the virus-containing medium was filtered through a 0.45 mM PVDF membrane (Millipore; Eschborn, Germany), concentrated on a Vivaspin 20 column (mol wt cutoff, 30,000 Da; PES; Sartorius; Goettingen, Germany), and used to infect 1 3 10 5 NIH 3T3 cells seeded in 6-well plates in the presence of polybrene (8 mg/ml). This procedure was repeated 8 hr later, yielding infection rates higher than 90%.
Reporter Assays and Western Blotting
Fifty thousand cells per 1 cm dish (12-well plate) were transfected with 25 ng luciferase reporter plasmid and 50 ng pRL-TK, together with 100 ng of the indicated plasmids in a total of 500 ng DNA, as described (Descot et al., 2008) . Statistical analysis was done by unpaired Student's t test.
Immunoblotting was done using anti-phospho-Erk (1:1000; Cell Signaling; Danvers, MA), anti-panErk (1:1000; Transduction Laboratories; Heidelberg, Germany), anti-tubulin (1:10000; Sigma), anti-HA peroxidase conjugate (1:700; Roche), anti-phospho-EGFR-Y1173 (1:1000; Cell Signaling), anti-phosphoHer2Y1248 (1:1000; Cell Signaling), anti-EGFR (1:2000; Biomol; Hamburg, Germany), anti-MAL (1:1000; homemade rabbit antiserum #79), and antiMig6 (1:1000; rabbit antiserum raised against GST-Mig6 [Hackel et al., 2001] or 1:1000, PE-16; Sigma) antibodies. Densitometric analysis of western blots was carried out using AIDA software (Raytest; Straubenhardt, Germany) and calculated as ratios to the control protein expression.
Quantitative RT-PCR RNA preparation (QIAGEN) and first-strand cDNA synthesis (ABgene; Epson, UK) were done according to the manufacturers' protocol. For cDNA synthesis, 1 mg of RNA and anchored oligo dT primers were used. For cDNA quantitation, one-fortieth of the RT reaction was mixed with gene-specific primers (0.5 mM) and Fast SYBR Green Master mix to a total volume of 15 ml. The PCR was carried out either on a LightCycler (Roche) or a StepOnePlus instrument (Applied Biosystems; Darmstadt, Germany), according to the manufacturer's instructions, and calculation was done using the DDCt method (Descot et al., 2008) .
ChIPs NIH 3T3 cells (10 7 ) were fixed with 1% formaldehyde for 10 min at RT. For each IP, one-fifth of the sonicated chromatin was diluted ten times and incubated with 3 mg of anti-SRF (G-20, Santa Cruz; Heidelberg, Germany) or homemade anti-MAL rabbit serum (#79), precoupled to 20 ml of Dynabeads (Invitrogen).
Immune complexes were captured for 2 hr at 4 C. DNA-protein complexes were eluted with 0.1 M NaHCO 3 /0.1% SDS, crosslinks were reversed overnight at 65 C, and DNA was purified using PCR Purification Kit (QIAGEN).
Immunoprecipitated DNA was analyzed using following primers: Mig6 (covers CArG-like element at À260): / (GCTCCCTGAGTTTCTTGGATC), ) (ATGC CGCTACCGAAGAGTTT); Mig6 control (covers first intron at +3160): / (AGT TCCAGTTCCTGTCATTGC), ) (CCCACTCCTCCTTTCTATCG). Primers for gapdh, vinc, and srf were published previously (Vartiainen et al., 2007) . Quantitation was done by real-time PCR and is shown as the percentage compared to input chromatin.
ACCESSION NUMBERS
The microarray data have been deposited at the GEO database, and the accession number is GSE17105. 
Supplemental Experimental Procedures Plasmids
The expression plasmids for SRF and MAL as well as the SRF reporter plasmids were described The plasmid for Myocardin was a gift from Richard Treismann (CR-UK, London), and the plasmid for RhoQ63L was a gift from Reinhard Faessler (MPI of Biochemistry, Martinsried, Germany).
Microarray Analysis
All experiments were performed in triplicate. Total cellular RNA was labeled and hybridized to Affymetrix Murine Genome 430 2.0 arrays (monitoring more than 45,000 transcripts) as recommended by the manufacturer. Raw fluorescence intensity files were generated with Affymetrix Microarraysuite version 5 software. Data were processed and analyzed with R and Bioconductor, as described (van Erp et al., 2006) . Quality control was performed with RNA degradation plots, MvA-Plots, sample clusters and Affymetrix control measures as implemented in the Bioconductor affy and simpleaffy packages (data not shown). Cell files were normalized with GC-RMA as implemented in the gcrma package (Wu and Irizarry, 2005) . Differentially expressed genes were identified by a permutation-based method using the SAM algorithm (Tusher et al., 2001) . Briefly, to control for multiple testing, a false discovery rate (FDR) was calculated as the percentage of genes falsely detected as differentially expressed among all genes detected as differentially expressed. The q value is the lowest FDR at which the gene is called significant. Genes were considered to be differentially expressed if they were detected at a false discovery rate of 5.43% for the GC-RMA analysis.
Phospho-JNK/p38 Analysis
NIH 3T3 cells were serum starved for 24 hr and then stimulated as indicated prior to preparation of total cell lysates. Immunoblotting was done using the anti-phospho-JNK (1:2000; Cell Signaling #9251), the anti-phospho-p38 (1:2000; Cell Signaling #9211), the anti-p38 (1:1000; Santa Cruz sc535), and the anti-JNK1 (1:1000; Santa Cruz sc474) antibodies.
Immunofluorescence Microscopy
Cells were fixed with acetone/methanol for 5 min at −20°C and blocked with 10% FCS, 1% gelatine, and 0.05% Triton X-100 in PBS. Staining was done using anti-Mig6 (1:1000; rabbit polyclonal antiserum #1573, raised against a Mig6 fragment; a gift from Ingvar Ferby, University College London) overnight at 4°C, and Alexa Fluor 546 anti-rabbit 1:1000 (Molecular Probes). Micrographs were taken using a Zeiss Axioplan 2 or Zeiss Axiovert with MetaVue software (Molecular Devices/Visitron).
Rho Involvement
Cell permeable Rho inhibitor Tat-C3 was prepared as described (Busche et al., 2008) . The promoter-reporter construct ranging from -726 to +1 and the heterologous promoter containing a -392 to -96 fragment in front of a TATA box were cotransfected with activated SRF VP16 into NIH 3T3 cells. The mutated promoter ΔCArG1 contains a deletion of the CArG box at -260 as described in Figure 3 , whilst the ΔCArG2 reporter contains a 10 bp deletion of the sequence -129CCCTTTAAGC-119, indicated by X. Shown is the relative luciferase activity, normalized to Renilla luciferase. 
